Navigation Links
Uptake Medical Receives CE Mark for InterVapor - Endoscopic Lung Volume Reduction for Treatment of Severe Emphysema - and Announces Positive Clinical Results
Date:9/26/2011

AMSTERDAM and TUSTIN, Calif., Sept. 26, 2011 /PRNewswire/ -- Uptake Medical® today announced it has received the CE Mark (Conformite Europeenne) for the InterVapor™ System - the first endoscopic lung volume reduction system for the treatment of severe emphysema that uses the body's natural healing processes without leaving foreign materials behind. The CE Mark will allow Uptake Medical to commercialize InterVapor in key markets within the European Community.

This announcement coincides with the presentation of the six-month results from the worldwide, multi-center VAPOR trial at the European Respiratory Society Annual Congress. The clinical trial data shows significant improvement in breathing capacity, shortness of breath, exercise capacity and quality of life. The results of this trial were presented during clinical sessions at the European Respiratory Society's Annual Congress on Sunday, September 25, 2011 at 10:45 AM in Amsterdam.

Emphysema is a progressive disease in which the lungs are permanently damaged. This leads to a condition called hyperinflation, which impacts breathing function and forces patients to take short, shallow breaths, severely impacting quality of life. The InterVapor System was developed in response to the needs of patients with severe emphysema and is designed to directly target the hyperinflation in the lungs.

The VAPOR study was an open label, single-arm trial of InterVapor (Bronchoscopic Thermal Vapor Ablation) in patients with upper lobe predominant emphysema. Primary endpoints measuring lung function improvement (FEV1) and health-related quality of life (St. George's Respiratory Questionnaire or SGRQ) achieved both statistical and clinical significance at six months.  Additionally, 83 percent of patients met a combined endpoint for clinical improvement.  

Efficacy was consistently demonstrated across all endpoints. Secondary endpoints demonstrated that patients treated with the InterVapor procedure have significant physiologic improvements (including decreased hyperinflation and gas trapping) as well as clinical improvements (reduced breathlessness and improved exercise capacity). All treatments were performed successfully without intra-procedural complications. Adverse events related to treatment included a temporary increase in respiratory symptoms in some patients, which generally resolved with standard medical management. Clinical data supports a favorable risk/benefit profile for the use of InterVapor in the treatment of patients with heterogeneous severe emphysema.

Felix Herth, MD, Chief, Department of Pulmonary Medicine, Thoraxklinik Heidelberg and primary investigator for the VAPOR study, is enthusiastic about the InterVapor data. "In a progressive and debilitating disease such as emphysema, it is important to show improvement across multiple measures as each metric indicates a different aspect of emphysema. A procedure that shows an 83 percent improvement when looking at several endpoints should provide new optimism for patients who are living with emphysema."

InterVapor is a minimally invasive procedure which treats hyperinflated parts of the lungs with heated water vapor. InterVapor triggers the body's natural healing process, gradually reducing the treated portion of the lungs and increasing the ability to breathe more fully. Unlike other approaches to lung volume reduction, InterVapor requires no foreign materials to be left behind in the lung which may require additional procedures.

King Nelson, President and Chief Executive Officer of Uptake Medical, stated, "We are extremely pleased to have received the CE Mark for InterVapor and continue to be encouraged by the positive results from our InterVapor technology. As the only endoscopic lung volume reduction procedure that uses a natural healing process without leaving foreign materials in the lung, we believe that InterVapor will play an important role in advancing treatments for emphysema. We have a unique opportunity to help patients with severe emphysema and we look forward to having the InterVapor System available to physicians and their patients."

The clinical trial investigators are Felix Herth, MD, Gregory Snell, MD, Peter Hopkins, MD, Kimberly Baker, MD, Christian Witt, MD, Mark H. Gotfried, MD, Arschang Valipour, MD, Manfred Wagner, MD, Franz Stanzel, MD, James Egan, MD, Steven Kesten, MD and Armin Ernst, MD. The results of the clinical trial were presented at the European Respiratory Society Annual Congress in the session titled, "Sustained Efficacy From 3 to 6 Months Following Bronchoscopic Thermal Vapor Ablation (BTVA) in the Treatment of Heterogeneous Emphysema" (abstract number 370) on Sunday, September 25, 2011, at 10:45 AM. A press conference discussing the results will be held on Monday, September 26, 2011, at 2:30 PM.

About Emphysema/COPD

The global incidence of Chronic Obstructive Pulmonary Disease (COPD), which includes emphysema, is on the rise, on pace to become the third leading cause of death by 2030. In the US, where nearly 5 million people are diagnosed with emphysema, it already holds this position with one person dying every 4 minutes. Debilitating and costly, nearly $50 billion was spent addressing the direct and indirect costs associated with COPD in the US in 2010.

About Uptake Medical

With headquarters in Tustin, CA, Uptake Medical® develops innovative medical technologies for the treatment of lung diseases. Its first product, InterVapor™, is the first and only approach to endoscopic lung volume reduction for people with severe emphysema that uses the body's natural healing process without leaving any foreign materials in the lung. In clinical studies, InterVapor has demonstrated clinically meaningful improvements in breathing function, exercise capacity and quality of life. InterVapor received the CE mark in September 2011 and plans to commercialize (in Europe and Australia) over the coming months. More information can be found at www.uptakemedical.com.

Uptake Medical, InterVapor, InterVapor Personalized Procedure Program and IP3 are registered trademarks and trademarks of Uptake Medical.


'/>"/>
SOURCE Uptake Medical
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. The Continued Uptake of Key Agents Such as Januvia, Bydureon and Byetta Will Drive The Type 2 Diabetes Drug Market to Nearly Double From $19 Billion in 2009 to $36 Billion in 2019
2. Introduction of New Products and Increased Uptake of Innovative Materials to Drive US Bone Graft Substitute Market to Nearly $2.3 Billion by 2015
3. Driven by the Uptake of Several Emerging Agents, the MRSA Drug Market Will Increase From $631 Million in 2009 to $752 Million in 2019
4. Uptake Medical Names J.C. MacRae as Chief Financial Officer
5. The Harley Medical Group Sees an Uptake in Surgery Bookings for Christmas
6. Uptake Medical Announces Scott Huennekens Elected to Board of Directors
7. Reportlinker Adds Pharmaceutical Key Trends 2011 - Generics Market Overview: Patent cliff set to drive global generic uptake despite tougher market conditions
8. Reportlinker Adds Opioids Market to 2017 - Steady Uptake of Oxycontin and High Incidence Of Diseases Such As Cancer And Arthritis to Drive the Market
9. Uptake Medical® Expands Executive Team, Announces European General Manager Lloyd Mencinger
10. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
11. You May Have a Thyroid Problem and Not Know It - Particularly If Youre Over 60, Says a New Harvard Medical School Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Research and Markets has announced the addition of the ... to their offering. ... World Market for Companion Diagnostics covers the world market for ... report includes the following: , World IVD ... (N. America, EU, ROW), 2015-2020 , World IVD Companion ...
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... 2016 Research and Markets has ... by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), ... Parenteral) - Global Forecast to 2021" report to ... The global pharmaceutical excipients market is projected to reach ... 6.1% in the forecast period 2016 to 2021. ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events ... turn to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. ... tools for healthy coping following a traumatic event. , Trauma sufferers tend to feel ...
(Date:6/24/2016)... MIAMI, Fla. (PRWEB) , ... June 24, 2016 , ... ... Florida Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this ... of Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this ...
(Date:6/24/2016)... , ... June 24, 2016 , ... People across the ... Genome magazine’s Code Talker Award, an essay contest in which patients and their families ... to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education ...
(Date:6/24/2016)... ... 24, 2016 , ... Strategic Capital Partners, LLC (SCP) in ... investment capital for emerging technology companies. SCP has delivered investment events and ... more than a million dollars of capital investment for five companies. ...
Breaking Medicine News(10 mins):